5/17
12:03 am
fbio
Fortress Biotech, Inc. (NASDAQ: FBIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Fortress Biotech, Inc. (NASDAQ: FBIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
5/16
02:12 pm
fbio
Fortress Biotech, Inc. (NASDAQ: FBIO) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $10.00 price target on the stock.
Low
Report
Fortress Biotech, Inc. (NASDAQ: FBIO) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $10.00 price target on the stock.
5/16
08:14 am
fbio
Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase [Yahoo! Finance]
Medium
Report
Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase [Yahoo! Finance]
5/16
08:00 am
fbio
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
Medium
Report
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
5/15
04:20 pm
fbio
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Low
Report
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
5/15
04:15 pm
fbio
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Low
Report
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
5/14
08:38 am
fbio
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation [Yahoo! Finance]
Medium
Report
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation [Yahoo! Finance]
5/14
08:30 am
fbio
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
Medium
Report
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
5/10
08:43 am
fbio
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates [Yahoo! Finance]
Low
Report
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates [Yahoo! Finance]
4/23
08:12 am
fbio
Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer [Yahoo! Finance]
Medium
Report
Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer [Yahoo! Finance]
4/12
02:04 am
fbio
Fortress Biotech, Inc. (NASDAQ: FBIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Fortress Biotech, Inc. (NASDAQ: FBIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
4/4
11:04 pm
fbio
Fortress Biotech, Inc. (NASDAQ: FBIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Neutral
Report
Fortress Biotech, Inc. (NASDAQ: FBIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/28
04:19 pm
fbio
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Medium
Report
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
3/28
04:05 pm
fbio
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Low
Report
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
3/28
11:13 am
fbio
Mustang Bio stock climbs 9% amid drug development update [Seeking Alpha]
Medium
Report
Mustang Bio stock climbs 9% amid drug development update [Seeking Alpha]
3/22
08:40 am
fbio
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Low
Report
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
3/19
08:37 am
fbio
Fortress Biotech, Inc. (NASDAQ: FBIO) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $5.00 price target on the stock.
Low
Report
Fortress Biotech, Inc. (NASDAQ: FBIO) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $5.00 price target on the stock.
3/18
08:17 am
fbio
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors [Yahoo! Finance]
Medium
Report
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors [Yahoo! Finance]
3/15
08:00 am
fbio
Fortress Biotech, Inc. (NASDAQ: FBIO) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $10.00 price target on the stock.
High
Report
Fortress Biotech, Inc. (NASDAQ: FBIO) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $10.00 price target on the stock.
3/12
08:52 am
fbio
Fortress Biotech to Participate in 36th Annual ROTH Conference [Yahoo! Finance]
Medium
Report
Fortress Biotech to Participate in 36th Annual ROTH Conference [Yahoo! Finance]
3/12
08:30 am
fbio
Fortress Biotech to Participate in 36th Annual ROTH Conference
Medium
Report
Fortress Biotech to Participate in 36th Annual ROTH Conference
3/4
08:42 am
fbio
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease [Yahoo! Finance]
Medium
Report
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease [Yahoo! Finance]
3/4
08:30 am
fbio
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
High
Report
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
2/17
08:40 am
fbio
Insider Stock Buying Reaches US$3.06m On Fortress Biotech [Yahoo! Finance]
Medium
Report
Insider Stock Buying Reaches US$3.06m On Fortress Biotech [Yahoo! Finance]